Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)

被引：0
|
作者：
Seidman, A. D.
Conlin, A. K.
Bach, A.
Brufsky, A. M.
Saleh, M. N.
Lake, D.
Dickler, M. N.
D'Andrea, G.
Traina, T. A.
Hudis, C. A.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Georgia Canc Specialists, Marietta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.1047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1047
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) plus capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
    Somer, B. G.
    Schwartzberg, L. S.
    Arena, F.
    Epperson, A.
    Fu, D.
    Fortner, B. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] A phase II study of weekly nanoparticle albumin-bound paclitaxel combined with cisplatin in patients with metastatic breast cancer
    Wang, Biyun
    Hu, Xi-Chun
    Sun, Si
    Zhang, Jian
    Tang, Lichen
    Wang, Zhong Hua
    Wang, Lei Ping
    Lv, Fangfang
    Zhang, Qunling
    Zheng, Chunlei
    Jia, Zhen
    Lu, Yunhua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Phase II Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer
    Takashima, Tsutomu
    Nakayama, Takahiro
    Yoshidome, Katsuhide
    Kawajiri, Hidemi
    Kamigaki, Shunji
    Tsurutani, Junji
    Arai, Takashi
    Ito, Toshikazu
    Komoike, Yoshihumi
    Doi, Takako
    Masuda, Norikazu
    Miyauchi, Keisuke
    Miyoshi, Yasuo
    Sakamoto, Junichi
    Morita, Satoshi
    Taguchi, Tetsuya
    ANTICANCER RESEARCH, 2014, 34 (07) : 3583 - 3588
  • [24] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer
    Loesch, David
    Asmar, Lina
    McIntyre, Kristi
    Doane, Lisa
    Monticelli, Michael
    Paul, Devchand
    Vukelja, Svetislava
    Orlando, Mauro
    Vaughn, LaTrice G.
    Zhan, Feng
    Boehm, Kristi A.
    O'Shaughnessy, Joyce A.
    CLINICAL BREAST CANCER, 2008, 8 (02) : 178 - 186
  • [26] Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer
    Luo, T.
    Zhong, X.
    He, P.
    Yan, X.
    Tian, T.
    Wei, B.
    Zhang, Z.
    Li, J.
    Zheng, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S331 - S331
  • [27] Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2-Positive Breast Cancer: The TRAIN Study.
    Sonke, G. S.
    Mandjes, I. A.
    Holtkamp, M.
    Schot, M.
    Oosterkamp, H. M.
    Wesseling, J.
    Vrancken, Peeters M-J T.
    Rodenhuis, S.
    Linn, S. C.
    CANCER RESEARCH, 2011, 71
  • [28] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer
    Yardley, Denise A.
    Raefsky, Eric
    Castillo, Raul
    Lahiry, Anup
    LoCicero, Richard
    Thompson, Dana
    Shastry, Mythili
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2011, 11 (05) : 297 - 305
  • [30] Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study
    van Ramshorst, Mette S.
    van Werkhoven, Erik
    Mandjes, Ingrid A. M.
    Schot, Margaret
    Wesseling, Jelle
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Terwogt, Jetske M. Meerum
    Bos, Monique E. M.
    Oosterkamp, Hendrika M.
    Rodenhuis, Sjoerd
    Linn, Sabine C.
    Sonke, Gabe S.
    EUROPEAN JOURNAL OF CANCER, 2017, 74 : 47 - 54
12345